---
document_datetime: 2025-12-02 06:12:41
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/zynrelef.html
document_name: zynrelef.html
version: success
processing_time: 0.1151232
conversion_datetime: 2025-12-26 20:16:12.063031
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Zynrelef

[RSS](/en/individual-human-medicine.xml/67361)

##### Withdrawn

This medicine's authorisation has been withdrawn

bupivacaine / meloxicam Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Zynrelef](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 5 October 2023, the European Commission withdrew the marketing authorisation for Zynrelef (bupivacaine / meloxicam) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Heron Therapeutics, B.V., which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Zynrelef was granted marketing authorisation in the EU on 24 September 2020 for the treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults.

The European Public Assessment Report (EPAR) for Zynrelef is updated to indicate that the marketing authorisation is no longer valid.

Expand section

Collapse section

## How is Zynrelef used?

Zynrelef is a prolonged-release solution that is applied to the wound during surgery before the wound is closed. Prolonged-release means that the active substances are released slowly over several hours after application.

The medicine can only be obtained with a prescription and it should be used in a setting (such as a hospital) where trained staff and equipment are available to treat patients who get side effects involving the heart or central nervous system.

For more information about using Zynrelef, see the package leaflet or contact your doctor or pharmacist.

## How does Zynrelef work?

Bupivacaine is a local anaesthetic which temporarily numbs the area to which it has been applied by blocking pain signals to the brain. Meloxicam, a non-steroidal anti-inflammatory drug (NSAID), reduces pain and inflammation and strengthens the effect of bupivacaine.

## What benefits of Zynrelef have been shown in studies?

Two main studies in 830 patients have shown that Zynrelef is effective at reducing pain from small to medium-sized wounds following surgery. The main measure of effectiveness was a total pain score for a 72-hour period, with lower scores indicating better pain control.

In the first study involving patients who had surgery to remove a bunion, the pain score in patients treated with Zynrelef was 323 compared with 445 for patients receiving placebo (a dummy treatment) and 393 for patients receiving bupivacaine (standard treatment). In the second study involving patients who had surgery to repair a hernia, the pain score was 269 with Zynrelef compared with 351 for patients receiving placebo and 342 for patients receiving bupivacaine. In both these studies Zynrelef had some effect in reducing the use of opioid pain medication after surgery.

## What are the risks associated with Zynrelef?

The most common side effect with Zynrelef (which may affect more than 1 in 10 people) is dizziness.

Zynrelef should not be used in patients with hypersensitivity (allergy) to the active substances or to any amide-type local anaesthetic or an NSAID including acetylsalicylic acid (also known as aspirin). The medicine should also not be used in women during the last 3 months of pregnancy, in patients who have undergone certain heart surgeries or who have severe heart failure (when the heart does not pump as well as it should), poor liver function or severe kidney failure (inability of the kidneys to work properly) that is not being treated with dialysis (to remove unwanted fluids and substances from the blood).

For the full list of side effects and restrictions with Zynrelef, see the package leaflet.

## Why is Zynrelef authorised in the EU?

Zynrelef has been shown to provide effective pain relief from small to medium-sized wounds after surgery. Its effect on reducing the need for opioid pain relief was considered modest but clinically significant. The medicine's side effects are similar to those of bupivacaine alone and are considered manageable. The European Medicines Agency therefore decided that Zynrelef's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Zynrelef?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zynrelef have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Zynrelef are continuously monitored. Side effects reported with the medicine are carefully evaluated and any necessary action taken to protect patients.

## Other information about Zynrelef

Zynrelef received a marketing authorisation valid throughout the EU on 24 September 2020.

Zynrelef : EPAR - Medicine overview

Reference Number: EMA/497953/2020

English (EN) (186.35 KB - PDF)

**First published:** 06/10/2020

**Last updated:** 22/11/2023

[View](/en/documents/overview/zynrelef-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-923)

български (BG) (241 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/bg/documents/overview/zynrelef-epar-medicine-overview_bg.pdf)

español (ES) (185.73 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/es/documents/overview/zynrelef-epar-medicine-overview_es.pdf)

čeština (CS) (222.53 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/cs/documents/overview/zynrelef-epar-medicine-overview_cs.pdf)

dansk (DA) (182.57 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/da/documents/overview/zynrelef-epar-medicine-overview_da.pdf)

Deutsch (DE) (190.92 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/de/documents/overview/zynrelef-epar-medicine-overview_de.pdf)

eesti keel (ET) (167.63 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/et/documents/overview/zynrelef-epar-medicine-overview_et.pdf)

ελληνικά (EL) (241.1 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/el/documents/overview/zynrelef-epar-medicine-overview_el.pdf)

français (FR) (188.87 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/fr/documents/overview/zynrelef-epar-medicine-overview_fr.pdf)

hrvatski (HR) (215.3 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/hr/documents/overview/zynrelef-epar-medicine-overview_hr.pdf)

italiano (IT) (182.49 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/it/documents/overview/zynrelef-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (227.13 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/lv/documents/overview/zynrelef-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (219.14 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/lt/documents/overview/zynrelef-epar-medicine-overview_lt.pdf)

magyar (HU) (213.65 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/hu/documents/overview/zynrelef-epar-medicine-overview_hu.pdf)

Malti (MT) (226.26 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/mt/documents/overview/zynrelef-epar-medicine-overview_mt.pdf)

Nederlands (NL) (186.76 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/nl/documents/overview/zynrelef-epar-medicine-overview_nl.pdf)

polski (PL) (220.83 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/pl/documents/overview/zynrelef-epar-medicine-overview_pl.pdf)

português (PT) (186.6 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/pt/documents/overview/zynrelef-epar-medicine-overview_pt.pdf)

română (RO) (218.59 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/ro/documents/overview/zynrelef-epar-medicine-overview_ro.pdf)

slovenčina (SK) (218.16 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/sk/documents/overview/zynrelef-epar-medicine-overview_sk.pdf)

slovenščina (SL) (218.63 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/sl/documents/overview/zynrelef-epar-medicine-overview_sl.pdf)

Suomi (FI) (176.91 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/fi/documents/overview/zynrelef-epar-medicine-overview_fi.pdf)

svenska (SV) (178.48 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/sv/documents/overview/zynrelef-epar-medicine-overview_sv.pdf)

Zynrelef : EPAR - Risk-management-plan summary

English (EN) (248.47 KB - PDF)

**First published:** 06/10/2020

**Last updated:** 22/11/2023

[View](/en/documents/rmp-summary/zynrelef-epar-risk-management-plan-summary_en.pdf)

## Product information

Zynrelef : EPAR - Product information

English (EN) (2.03 MB - PDF)

**First published:** 06/10/2020

**Last updated:** 22/11/2023

[View](/en/documents/product-information/zynrelef-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-232)

български (BG) (2.23 MB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/bg/documents/product-information/zynrelef-epar-product-information_bg.pdf)

español (ES) (1.92 MB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/es/documents/product-information/zynrelef-epar-product-information_es.pdf)

čeština (CS) (2.08 MB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/cs/documents/product-information/zynrelef-epar-product-information_cs.pdf)

dansk (DA) (1.94 MB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/da/documents/product-information/zynrelef-epar-product-information_da.pdf)

Deutsch (DE) (2.09 MB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/de/documents/product-information/zynrelef-epar-product-information_de.pdf)

eesti keel (ET) (1.92 MB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/et/documents/product-information/zynrelef-epar-product-information_et.pdf)

ελληνικά (EL) (5.92 MB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/el/documents/product-information/zynrelef-epar-product-information_el.pdf)

français (FR) (2.07 MB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/fr/documents/product-information/zynrelef-epar-product-information_fr.pdf)

hrvatski (HR) (2.02 MB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/hr/documents/product-information/zynrelef-epar-product-information_hr.pdf)

íslenska (IS) (1.81 MB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/is/documents/product-information/zynrelef-epar-product-information_is.pdf)

italiano (IT) (1.97 MB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/it/documents/product-information/zynrelef-epar-product-information_it.pdf)

latviešu valoda (LV) (2.24 MB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/lv/documents/product-information/zynrelef-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.12 MB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/lt/documents/product-information/zynrelef-epar-product-information_lt.pdf)

magyar (HU) (2.19 MB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/hu/documents/product-information/zynrelef-epar-product-information_hu.pdf)

Malti (MT) (2.61 MB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/mt/documents/product-information/zynrelef-epar-product-information_mt.pdf)

Nederlands (NL) (1.93 MB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/nl/documents/product-information/zynrelef-epar-product-information_nl.pdf)

norsk (NO) (1.88 MB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/no/documents/product-information/zynrelef-epar-product-information_no.pdf)

polski (PL) (2.29 MB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/pl/documents/product-information/zynrelef-epar-product-information_pl.pdf)

português (PT) (1.88 MB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/pt/documents/product-information/zynrelef-epar-product-information_pt.pdf)

română (RO) (2.21 MB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/ro/documents/product-information/zynrelef-epar-product-information_ro.pdf)

slovenčina (SK) (2.34 MB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/sk/documents/product-information/zynrelef-epar-product-information_sk.pdf)

slovenščina (SL) (2.05 MB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/sl/documents/product-information/zynrelef-epar-product-information_sl.pdf)

Suomi (FI) (2.07 MB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/fi/documents/product-information/zynrelef-epar-product-information_fi.pdf)

svenska (SV) (1.86 MB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/sv/documents/product-information/zynrelef-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/00010880/202303 05/10/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Zynrelef : EPAR - All authorised presentation

English (EN) (54.21 KB - PDF)

**First published:** 06/10/2020

**Last updated:** 22/11/2023

[View](/en/documents/all-authorised-presentations/zynrelef-epar-all-authorised-presentation_en.pdf)

[Other languages (24)](#file-language-dropdown-949)

български (BG) (96.58 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/bg/documents/all-authorised-presentations/zynrelef-epar-all-authorised-presentation_bg.pdf)

español (ES) (63.51 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/es/documents/all-authorised-presentations/zynrelef-epar-all-authorised-presentation_es.pdf)

čeština (CS) (89.86 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/cs/documents/all-authorised-presentations/zynrelef-epar-all-authorised-presentation_cs.pdf)

dansk (DA) (66.69 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/da/documents/all-authorised-presentations/zynrelef-epar-all-authorised-presentation_da.pdf)

Deutsch (DE) (63.42 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/de/documents/all-authorised-presentations/zynrelef-epar-all-authorised-presentation_de.pdf)

eesti keel (ET) (62.86 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/et/documents/all-authorised-presentations/zynrelef-epar-all-authorised-presentation_et.pdf)

ελληνικά (EL) (94.12 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/el/documents/all-authorised-presentations/zynrelef-epar-all-authorised-presentation_el.pdf)

français (FR) (67.39 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/fr/documents/all-authorised-presentations/zynrelef-epar-all-authorised-presentation_fr.pdf)

hrvatski (HR) (83.16 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/hr/documents/all-authorised-presentations/zynrelef-epar-all-authorised-presentation_hr.pdf)

íslenska (IS) (62.58 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/is/documents/all-authorised-presentations/zynrelef-epar-all-authorised-presentation_is.pdf)

italiano (IT) (62.65 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/it/documents/all-authorised-presentations/zynrelef-epar-all-authorised-presentation_it.pdf)

latviešu valoda (LV) (86.89 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/lv/documents/all-authorised-presentations/zynrelef-epar-all-authorised-presentation_lv.pdf)

lietuvių kalba (LT) (86.04 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/lt/documents/all-authorised-presentations/zynrelef-epar-all-authorised-presentation_lt.pdf)

magyar (HU) (83.62 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/hu/documents/all-authorised-presentations/zynrelef-epar-all-authorised-presentation_hu.pdf)

Malti (MT) (97.08 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/mt/documents/all-authorised-presentations/zynrelef-epar-all-authorised-presentation_mt.pdf)

Nederlands (NL) (54.02 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/nl/documents/all-authorised-presentations/zynrelef-epar-all-authorised-presentation_nl.pdf)

norsk (NO) (59.56 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/no/documents/all-authorised-presentations/zynrelef-epar-all-authorised-presentation_no.pdf)

polski (PL) (88.47 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/pl/documents/all-authorised-presentations/zynrelef-epar-all-authorised-presentation_pl.pdf)

português (PT) (64.35 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/pt/documents/all-authorised-presentations/zynrelef-epar-all-authorised-presentation_pt.pdf)

română (RO) (80.94 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/ro/documents/all-authorised-presentations/zynrelef-epar-all-authorised-presentation_ro.pdf)

slovenčina (SK) (78.49 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/sk/documents/all-authorised-presentations/zynrelef-epar-all-authorised-presentation_sk.pdf)

slovenščina (SL) (82.08 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/sl/documents/all-authorised-presentations/zynrelef-epar-all-authorised-presentation_sl.pdf)

Suomi (FI) (63.77 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/fi/documents/all-authorised-presentations/zynrelef-epar-all-authorised-presentation_fi.pdf)

svenska (SV) (62.89 KB - PDF)

**First published:**

06/10/2020

**Last updated:**

22/11/2023

[View](/sv/documents/all-authorised-presentations/zynrelef-epar-all-authorised-presentation_sv.pdf)

## Product details

Name of medicine Zynrelef Active substance

- bupivacaine
- meloxicam

International non-proprietary name (INN) or common name

- bupivacaine
- meloxicam

Therapeutic area (MeSH) Pain, Postoperative Anatomical therapeutic chemical (ATC) code N01B

### Pharmacotherapeutic group

Anesthetics

### Therapeutic indication

Zynrelef is indicated for treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults (see section 5.1).

## Authorisation details

EMA product number EMEA/H/C/005205 Marketing authorisation holder

Heron Therapeutics, B.V.

Herengracht 500

Opinion adopted 23/07/2020 Marketing authorisation issued 24/09/2020 Withdrawal of marketing authorisation 05/10/2023 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Zynrelef : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (300.01 KB - PDF)

**First published:** 16/06/2022

**Last updated:** 22/11/2023

[View](/en/documents/procedural-steps-after/zynrelef-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Zynrelef-H-C-PSUSA-00010880-202209 : EPAR - Scientific conclusions and grounds for the variation to the  terms of the marketing authorisation

Reference Number: EMA/192804/2023

English (EN) (187.81 KB - PDF)

**First published:** 28/06/2023

**Last updated:** 22/11/2023

[View](/en/documents/scientific-conclusion/zynrelef-h-c-psusa-00010880-202209-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Zynrelef : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/450646/2020

English (EN) (10.11 MB - PDF)

**First published:** 06/10/2020

**Last updated:** 22/11/2023

[View](/en/documents/assessment-report/zynrelef-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Zynrelef

Adopted

Reference Number: EMA/CHMP/367342/2020

English (EN) (157.86 KB - PDF)

**First published:** 24/07/2020

**Last updated:** 22/11/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-zynrelef_en.pdf)

#### News on Zynrelef

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2020) 24/07/2020

**This page was last updated on** 22/11/2023

## Share this page

[Back to top](#main-content)